0001493152-24-011527.txt : 20240327 0001493152-24-011527.hdr.sgml : 20240327 20240327164535 ACCESSION NUMBER: 0001493152-24-011527 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240327 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240327 DATE AS OF CHANGE: 20240327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PALISADE BIO, INC. CENTRAL INDEX KEY: 0001357459 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 522007292 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33672 FILM NUMBER: 24791484 BUSINESS ADDRESS: STREET 1: 7750 EL CAMINO REAL, SUITE 5200 CITY: CARLSBAD STATE: CA ZIP: 92009 BUSINESS PHONE: (858) 704-4900 MAIL ADDRESS: STREET 1: 7750 EL CAMINO REAL, SUITE 5200 CITY: CARLSBAD STATE: CA ZIP: 92009 FORMER COMPANY: FORMER CONFORMED NAME: Seneca Biopharma, Inc. DATE OF NAME CHANGE: 20200127 FORMER COMPANY: FORMER CONFORMED NAME: Neuralstem, Inc. DATE OF NAME CHANGE: 20060324 8-K 1 form8-k.htm
false 0001357459 0001357459 2024-03-27 2024-03-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 27, 2024 (March 22, 2024)

 

PALISADE BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

 

Delaware   001-33672   52-2007292

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

7750 El Camino Real

Suite 2A

   
Carlsbad, California   92009
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (858) 704-4900

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   PALI   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 results of Operations and Financial Condition

 

On March 26, 2024, Palisade Bio, Inc. (the “Company”) reported its financial results for the year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.01 and is incorporated herein by reference.

 

The information furnished under Items 2.02, including the accompanying Exhibit 99.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing rule or Standard; Transfer of Listing.

 

On March 22, 2024, the Company received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with the audit committee requirements set forth in Nasdaq Listing Rule 5605.

 

More specifically, as of the date of the Notice, the audit committee consists of only two (2) members, both of which are “independent directors,” as that term is defined in Nasdaq Listing Rule 5605(a)(2). Per Nasdaq Rules, the audit committee is required to be comprised of three (3) independent directors. The Notice states that, consistent with Nasdaq Listing Rules 5605(b)(1)(A) and Rule 5605(c)(4), Nasdaq will provide the Company a cure period in order to regain compliance (i) until the earlier of the Company’s next annual shareholders’ meeting or March 4, 2025, or (ii) if the next annual shareholders’ meeting is held before September 3, 2024, then the Company must evidence compliance no later than September 3, 2024.

 

The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On March 25, 2024, the Company held a virtual special meeting of its shareholders (“Special Meeting”) at 10:00 a.m. Pacific Time. Shareholders of record as of the close of business on February 2, 2024 (“Record Date”) were entitled to vote. As of the Record Date, 12,129,907 shares of the Company’s common stock were issued, outstanding, and entitled to vote, of which 6,583,805 shares of common stock, constituting a quorum, were represented at the meeting, in person or by proxy. The final results of the shareholder vote on the proposal brought before the Special Meeting was as follows:

 

Proposal 1. The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect, at the discretion of the Company’s Board of Directors: a reverse split of the Company’s common stock, at a ratio not less than 1-for-2 and not greater than 1-for-15, with the exact ratio to be set within that range at the discretion of the Board of Directors, without further approval or authorization of our shareholders, and to be effected on or before December 31, 2024, was approved by a majority of votes cast at the Special Meeting, based upon the following votes:

 

            Broker  
Votes For   Votes Against   Abstentions   Non-Votes  
  4,056,142     2,488,183     39,480      

 

Item 9.01 Financial Statement and Exhibits.

 

Exhibit No.   Description
99.01   Press Release dated March 27, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 27, 2024 Palisade Bio, Inc.
     
    /s/ J.D. Finley
  By: J.D. Finley
    Chief Executive Officer

 

 

EX-99.01 2 ex99-01.htm

 

Exhibit 99.01

 

 

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

 

– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end

 

– Formation of Clinical Advisory Board

 

– Sufficient cash on hand to execute on business plan and achieve significant clinical milestones into 2025

 

Carlsbad, CA – March 27, 2024Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a pre-clinical biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the full year 2023 and provided a corporate update.

 

Recent Highlights

 

  The Company formed its Clinical Advisory Board and appointed preeminent Key Opinion Leaders, Bruce Sands, MD, MS and Florian Rieder, MD;
  The exercise in February 2024, of 3,422,286 previously issued warrants to purchase common stock resulting in gross cash proceeds to the Company of $2.5 million;
  Presentation of positive preclinical data of its lead asset, PALI-2108 at the 2024 Crohn’s & Colitis Congress; and
  Giiant Pharma, Inc., the Company’s joint development partner, received the second milestone payment to assist in funding PALI-2108 from the US Crohn’s and Colitis Foundation, through its IBD Ventures program.

 

“2023 was a transformative year for Palisade Bio as we strategically shifted into the autoimmune, inflammatory, and fibrotic disease space, with the focus on our precision medicine approach in inflammatory bowel disease,” commented J.D. Finley, Chief Executive Officer. “As a result of the progress made by our development team, we are on track to launch the Phase 1 study of PALI-2108 by the end of 2024. We are looking forward to the advancement of our lead program to bring our product candidates into clinical trials and to increase our value for all stakeholders.”

 

PALI-2108 Development Program

 

The Company continues to advance its lead program, PALI-2108, for the treatment of moderate-to-severe ulcerative colitis (UC) toward a Phase 1 clinical study. PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.

 

 

 

 

Upcoming Target Milestones

 

  Complete ongoing IND/CTA-enabling tox studies by the end of the second quarter of 2024;
  Complete nonclinical IND/CTA-enabling activities by the end of the third quarter of 2024;
  Submit initial IND/CTA prior to the end of 2024; and
  Initiate Phase 1a/b prior to the end of 2024.

 

Precision Medicine Approach

 

Additionally, the Company is in the process of developing a genetic- or biomarker-based precision medicine approach that, if developed, will aid patients and physicians in selecting patients most likely to respond to PDE4 inhibitor therapy with PALI-2108. The Company is working with a strategic collaborator on development and has completed curation of a pipeline including over 1600 UC patients clinical and biomarker data and is in ongoing discussions with potential partners with access to additional patient data to support development of an FDA-approved test. The Company plans to leverage this expertise and infrastructure to fuel a growing pipeline of validated and high-priority autoimmune, inflammatory, and fibrotic disease product candidates.

 

Summary of Financial Results for the Year Ended December 31, 2023

 

As of December 31, 2023, the Company had cash, cash equivalents and restricted cash of $12.5 million. The Company believes it has sufficient cash to fund its currently planned operations into the first quarter of 2025.

 

Net operating loss was $13.1 million for the year ended December 31, 2023 compared to $15.7 million for the year ended December 31, 2022. Included in the net operating loss for the year ended December 31, 2023 was license revenue of $0.3 million, of which there was none in 2022, and restructuring costs of $0.2 million in 2023, compared to restructuring costs of $0.4 million in 2022.

 

Research and development expenses were $6.9 million for the year ended December 31, 2023, an increase of $0.3 million, or approximately 5% compared to the year ended December 31, 2022. The year-over-year increase is attributable to increased costs associated with the Giiant License Agreement, which we entered into on September 1, 2023, as well an increase in employee-related costs and employee recruiting costs, which were partially offset by a decrease in costs directly related to our development of LB1148, which we ceased in August of 2023.

 

General and administrative expenses decreased from $8.8 million for the year ended December 31, 2022 to $6.2 million for the year ended December 31, 2023. The decrease of $2.6 million, or 26%, was primarily as a result of cost-saving opportunities implemented by us in the third and fourth quarters of 2022, including those associated with the 2022 Cost-Reduction Plan. General and administrative employee compensation costs for the year ended December 31, 2023 decreased by approximately $1.4 million compared to the year ended December 31, 2022, primarily due to an approximately $0.9 million decrease in salaries and benefits and an approximately $0.5 million decrease in stock-based compensation expense. Other decreases in general and administrative expenses for the year ended December 31, 2023 compared to the year ended December 31, 2022 include: (i) an approximately $0.3 million decrease in professional fees, including accounting and legal fees and financial printing costs, (ii) an approximately $0.3 million decrease in investor and public relations costs and shareholder services costs, (iii) an approximately $0.2 million decrease in consultants and contract labor costs, (iv) an approximately $0.2 million decrease in general and administrative employee recruiting costs, and (v) an approximately $0.2 million decrease in insurance costs.

 

 

 

 

About Palisade Bio

 

Palisade Bio is a pre-clinical biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.

 

Forward Looking Statements

 

This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully develop our licensed technologies; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of the COVID-19 pandemic or any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company’s ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

 

Investor Relations Contact

 

JTC Team, LLC

Jenene Thomas

833-475-8247

PALI@jtcir.com

 

 

 

 

Palisade Bio, Inc.

Consolidated Balance Sheets (Unaudited)

(in thousands, except share and per share amounts)

 

   December 31, 
   2023   2022 
         
ASSETS          
Current assets:          
Cash and cash equivalents  $12,432   $12,383 
Prepaid expenses and other current assets   896    2,350 
Total current assets   13,328    14,733 
Restricted cash   26    26 
Property and equipment, net   10    10 
Operating lease right-of-use asset   198    300 
Other noncurrent assets   490    694 
Total assets  $14,052   $15,763 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $698   $1,759 
Accrued liabilities   831    574 
Accrued compensation and benefits   778    486 
Current portion of operating lease liability   121    105 
Insurance financing debt   158    88 
Total current liabilities   2,586    3,012 
Warrant liability   2    61 
Contingent consideration obligation   61     
Operating lease liability, net of current portion   90    211 
Total liabilities   2,739    3,284 
Commitments and contingencies          
Stockholders’ equity:          
Series A Convertible Preferred Stock, $0.01 par value,
7,000,000 shares authorized; 200,000 issued and
outstanding at December 31, 2023 and December 31, 2022
   2    2 
Common stock, $0.01 par value; 280,000,000 shares authorized;
9,270,894 and 2,944,306 shares issued and outstanding
at December 31, 2023 and December 31, 2022, respectively
   93    30 
Additional paid-in capital   132,724    121,637 
Accumulated deficit   (121,506)   (109,190)
Total stockholders’ equity   11,313    12,479 
Total liabilities and stockholders’ equity  $14,052   $15,763 

 

 

 

 

Palisade Bio, Inc.

Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share amounts)

 

   Year Ended December 31, 
   2023   2022 
License revenue  $250   $ 
Operating expenses:           
Research and development    6,893    6,547 
General and administrative    6,202    8,764 
Restructuring costs    225    410 
Total operating expenses    13,320    15,721 
Loss from operations    (13,070)   (15,721)
Other income (expense):           
Interest expense   (15)   (13)
Other income    785    2,584 
Loss on issuance of warrants       (1,110)
Total other income, net    770    1,461 
Net loss   $(12,300)  $(14,260)
           
Net loss available to common stockholders   $(12,316)  $(14,548)
Basic and diluted weighted average shares used in computing
basic and diluted net loss per common share
   6,840,213    880,311 
Basic and diluted net loss per common share  $(1.80)  $(16.53)

 

 

 

 

Palisade Bio, Inc.

Consolidated Statements of Cash Flows (Unaudited)

(in thousands, except share and per share amounts)

 

   Year Ended December 31, 
   2023   2022 
     
Net loss  $(12,300)  $(14,260)
Adjustments to reconcile net loss to net cash used in operating activities:           
Depreciation   4    3 
Noncash operating lease expense    102    164 
Loss on issuance of warrants       1,110 
Fair value of contingent consideration obligation    204     
Change in fair value of warrant liabilities    (59)   (2,426)
Stock-based compensation and related charges    624    1,032 
Other   (108)   (233)
Changes in operating assets and liabilities:           
Prepaid and other current assets and other noncurrent assets    705    1,027 
Accounts payable and accrued liabilities    (492)   399 
Accrued compensation    292    (25)
Operating lease liabilities    (105)   (151)
Net cash used in operating activities    (11,133)   (13,360)
Cash flows from investing activities:           
Purchases of property and equipment   (4)   (10)
Net cash used in investing activities    (4)   (10)
Cash flows from financing activities:          
Payments on insurance financing debt    (391)   (790)
Proceeds from issuance of common stock and warrants   9,419    14,401 
Proceeds from the exercise of warrants    2,758    2,274 
Payment of equity issuance costs   (617)   (627)
Proceeds from issuance of common stock under Employee Stock Purchase Plan    17     
Net cash provided by financing activities    11,186    15,258 
Net increase in cash, cash equivalents and restricted cash    49    1,888 
Cash, cash equivalents and restricted cash, beginning of year    12,409    10,521 
Cash, cash equivalents and restricted cash, end of year   $12,458   $12,409 
Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:           
Cash and cash equivalents   $12,432   $12,383 
Restricted cash    26    26 
Total cash, cash equivalents and restricted cash   $12,458   $12,409 

 

 

 

GRAPHIC 3 ex99-01_001.jpg begin 644 ex99-01_001.jpg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pali-20240327.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 pali-20240327_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 pali-20240327_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 27, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 27, 2024
Entity File Number 001-33672
Entity Registrant Name PALISADE BIO, INC.
Entity Central Index Key 0001357459
Entity Tax Identification Number 52-2007292
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7750 El Camino Real
Entity Address, Address Line Two Suite 2A
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92009
City Area Code (858)
Local Phone Number 704-4900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol PALI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://palisadebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm pali-20240327.xsd pali-20240327_lab.xml pali-20240327_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "PALI", "nsuri": "http://palisadebio.com/20240327", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "pali-20240327.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "pali-20240327_lab.xml" ] }, "presentationLink": { "local": [ "pali-20240327_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://palisadebio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://palisadebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001493152-24-011527-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-011527-xbrl.zip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end XML 18 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001357459 2024-03-27 2024-03-27 iso4217:USD shares iso4217:USD shares false 0001357459 8-K 2024-03-27 PALISADE BIO, INC. DE 001-33672 52-2007292 7750 El Camino Real Suite 2A Carlsbad CA 92009 (858) 704-4900 false false false false Common Stock, par value $0.01 per share PALI NASDAQ false